CatalYm has announced the closure of an oversubscribed EUR50 million Series C financing round that was co-led by new investors, Brandon Capital and Jeito Capital, with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. …
Australian venture capital fund joins partners in backing new immunotherapy
November 24, 2022 Latest NewsAustralian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 26 September
September 26, 2025 - - Podcast -
Waiting for any impact. Why the Albanese Government will hold fire on 'MFN'
September 26, 2025 - - Latest News -
Boehringer Ingelheim pushes for patient voices to lead policy reform
September 26, 2025 - - Latest News -
TGA consulting on the ongoing need for paper product information inserts
September 25, 2025 - - Latest News -
Gene therapy shows early promise in slowing Huntington’s Disease
September 25, 2025 - - Australian Biotech -
Federal minister to address AusBiotech International Conference as sector marks critical juncture
September 25, 2025 - - Australian Biotech -
Recce Pharmaceuticals begins patient dosing in pivotal diabetic foot infection trial
September 25, 2025 - - Australian Biotech